-
公开(公告)号：EP3915641A1
公开(公告)日：2021-12-01
申请号：EP20305555.3
申请日：2020-05-27
摘要： Novels antibodies, preferably monoclonal antibodies, or antigen-binding fragments thereof, said antibody or fragment thereof specifically binding to CD5. These antibodies may be used as a medicament, especially in the treatment of diseases in immunomodulation, inflammation, virology, infectiology, autoimmunity and oncology domains. Immune cells and/or cancer cells targeted by the invention are expressing CD5 antigen. These antibodies may be in particular chimeric or humanized. The invention also relates to pharmaceutical compositions, such as immunomodulator, anti-cancerous and anti-infectious compositions, containing such an antibody or antigen-binding fragment and methods of use of these, either for laboratory work, in drug manufacturing, such as in cell therapy cells production, or for medical treatment.
-
公开(公告)号：EP3461843A3
公开(公告)日：2019-04-24
申请号：EP18192521.5
申请日：2011-07-18
IPC分类号： C07K16/28 , A61K39/395
摘要： The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialylated glycoform. The present invention also relates to the use of these antibodies in the treatment, prevention or management of disease or disorder, such as cancer, especially a B-cell malignancy, and auto-immune disease.
-
公开(公告)号：EP3444272A1
公开(公告)日：2019-02-20
申请号：EP17306073.2
申请日：2017-08-17
摘要： The invention relates to the use of an anti-CK8 antibody alone or in combination therapy (with another antibody and/or chemotherapeutic agent) to (1) treat solid tumours expressing CK8 having wild-type K-Ras (not mutated as disclosed herein) and (2) treat solid tumours expressing CK8 having K-Ras mutation as disclosed herein. The invention also relates to the use of anti-CK8 antibodies having internalizing property, allowing to deliver cytotoxic agent coupled to antibody for the treatment of CK8 positive solid tumours, having wild-type K-Ras (not mutated as disclosed herein) or having K-Ras mutation as disclosed herein.
-
公开(公告)号：EP2596024B1
公开(公告)日：2018-12-26
申请号：EP11736051.1
申请日：2011-07-18
申请人： International-Drug-Development-Biotech , Université Claude Bernard Lyon 1 , Hospices Civils de Lyon
IPC分类号： C07K16/28
CPC分类号： C07K16/2896 , C07K16/2803 , C07K2317/24 , C07K2317/41 , C07K2317/524 , C07K2317/73 , C07K2317/92
摘要： The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and/or presence of sialic acid, high ADCC function and no CDC. The present invention also relates to the use of these antibodies in the treatment, prevention or management of diseases or disorders, such as cancer, especially a B-cell malignancy and auto-immune disease.
-
5.发明公开ANTI-CD19 ANTIBODY HAVING ADCC FUNCTION WITH IMPROVED GLYCOSYLATION PROFILE 审中-公开抗体CD19抗原激素MIT ADCC-FUNKTION UND VERBESSERTEM GLYKOSYLIERUNGSPROFIL
公开(公告)号：EP2596024A1
公开(公告)日：2013-05-29
申请号：EP11736051.1
申请日：2011-07-18
申请人： International-Drug-Development-Biotech , Université Claude Bernard Lyon 1 , Les Hospices Civils de Lyon
CPC分类号： C07K16/2896 , C07K16/2803 , C07K2317/24 , C07K2317/41 , C07K2317/524 , C07K2317/73 , C07K2317/92
摘要： The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and/or presence of sialic acid, high ADCC function and no CDC. The present invention also relates to the use of these antibodies in the treatment, prevention or management of diseases or disorders, such as cancer, especially a B-cell malignancy and auto-immune disease.
摘要翻译： 本发明涉及具有相对于野生型Fc区具有特定氨基酸修饰的变体Fc区的抗CD19抗体，其赋予一种或几种有用的效应子功能。 本发明特别涉及包含这种变体Fc区的嵌合，人源化或全人抗CD19抗体。 其有利地涉及具有有趣和有价值的糖基化谱，特别是低岩藻糖水平和/或高寡甘露糖水平和/或唾液酸，高ADCC功能的存在和没有CDC的抗体。 本发明还涉及这些抗体在治疗，预防或治疗诸如癌症，特别是B细胞恶性肿瘤和自身免疫疾病的疾病或病症中的用途。
-
6.发明公开Method to improve glycosylation profile for antibody 审中-公开Verfahren zur Verbesserung des GlykosylierungsprofilsfüreinenAntikörper
公开(公告)号：EP2409989A1
公开(公告)日：2012-01-25
申请号：EP10305795.6
申请日：2010-07-19
CPC分类号： C12P21/02 , C07K16/00 , C07K2317/14 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to the production of recombinant glycoproteins or antibodies that have an improved glycosylation profile and effector functions such as ADCC and/or CDC. The present invention is in particular related to the production of glycoproteins or antibodies having a valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and /or presence of sialic acid to the glycans.
摘要翻译： 本发明涉及具有改进的糖基化谱和效应子功能如ADCC和/或CDC的重组糖蛋白或抗体的生产。 本发明特别涉及具有有价值的糖基化分布，特别是低岩藻糖水平和/或高寡甘露糖水平和/或唾液酸存在于聚糖上的糖蛋白或抗体的产生。
-
公开(公告)号：EP3825330A1
公开(公告)日：2021-05-26
申请号：EP19306488.8
申请日：2019-11-19
发明人： VERMOT-DESROCHES, Claudine , BRESSON, Corinne , ROUSSET, Carine , VUILLERMOZ, Boris , SUBIGER, Olivier
摘要： The invention relates to the fields of immunology, oncology, and more specifically, to antibodies that can be used in the treatment of various cancers, more particularly cancers expressing CD117 antigen. These antibodies or antigen-binding molecules may be monoclonal antibodies or binding fragments thereof, they may be in particular chimeric or humanized. These antibodies may be antagonistic. The invention also relates to anticancerous or pharmaceutical compositions containing an antibody according to this invention and methods of use of these, either for laboratory work or for medical treatment.
-
8.发明公开Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof 审中-公开针对DR5家庭，双特异性或多价抗体抗DR5家庭和它们的使用方法抗体
公开(公告)号：EP2684896A1
公开(公告)日：2014-01-15
申请号：EP12305821.6
申请日：2012-07-09
发明人： Vermot-Desroches, Claudine Brigitte Fernande , Subiger, Olivier Frédéric , Bourdin, Laurence Françoise Jeanne-Marie
IPC分类号： C07K16/28
CPC分类号： C07K16/2878 , A61K2039/507 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/75
摘要： Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells.
摘要翻译： 抗DR5家族成员的抗体和双特异性抗体包含一个或多个抗DR5家族成员的抗体是游离缺失盘。 这些抗体可以用来触发DR5阳性细胞的细胞死亡。
-
9.发明公开ANTI-CD19 ANTIBODY HAVING ADCC AND CDC FUNCTIONS AND IMPROVED GLYCOSYLATION PROFILE 有权抗CD19抗原棉花麻醉药物疫苗接种疫苗免疫球蛋白
公开(公告)号：EP2595662A1
公开(公告)日：2013-05-29
申请号：EP11732491.3
申请日：2011-07-18
CPC分类号： C07K16/3061 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2887 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/77
摘要： The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and/or higher level of sialylated glycoform. The present invention also relates to the use of these antibodies in the treatment, prevention or management of disease or disorder, such as cancer, especially a B-cell malignancy, and auto-immune disease.
摘要翻译： 本发明涉及具有相对于野生型Fc区具有特定氨基酸修饰的变体Fc区的抗CD19抗体，其赋予一种或几种有用的效应子功能。 本发明特别涉及包含这种变体Fc区的嵌合，人源化或全人抗CD19抗体。 其有利地涉及具有有趣和有价值的糖基化谱，特别是低岩藻糖水平和/或高寡甘露糖水平和/或更高水平的唾液酸化糖型的抗体。 本发明还涉及这些抗体在治疗，预防或治疗疾病或病症如癌症，特别是B细胞恶性肿瘤和自身免疫疾病中的用途。
-
公开(公告)号：EP3461843A2
公开(公告)日：2019-04-03
申请号：EP18192521.5
申请日：2011-07-18
IPC分类号： C07K16/28 , A61K39/395
摘要： The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialylated glycoform. The present invention also relates to the use of these antibodies in the treatment, prevention or management of disease or disorder, such as cancer, especially a B-cell malignancy, and auto-immune disease.
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.023 秒)
